tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |
| Dinçkan A et al. | Evaluation of the first 100 liver transplantations. | 2008 | Turk J Gastroenterol | pmid:18386237 |
| Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
| Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
| Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
| Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
| Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
| Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
| Dumont FJ et al. | A tacrolimus-related immunosuppressant with reduced toxicity. | 1998 | Transplantation | pmid:9448138 |
| Mieles L et al. | Interaction between FK506 and clotrimazole in a liver transplant recipient. | 1991 | Transplantation | pmid:1721250 |
| Levy G et al. | Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. | 2004 | Transplantation | pmid:15201658 |
| Adams PS et al. | Postoperative cardiac tamponade after kidney transplantation: a possible consequence of alemtuzumab-induced cytokine release syndrome. | 2013 | Transplantation | pmid:23380870 |
| Ajiki T et al. | Generation of donor hematolymphoid cells after rat-limb composite grafting. | 2003 | Transplantation | pmid:12640301 |
| Tsuchiya N et al. | Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. | 2004 | Transplantation | pmid:15502717 |
| Takahara S et al. | The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. | 1992 | Transplantation | pmid:1373537 |
| Shield CF et al. | Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. | 1997 | Transplantation | pmid:9422413 |
| David-Neto E et al. | The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. | 2007 | Transplantation | pmid:17627237 |
| Al-Uzri A et al. | Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). | 2001 | Transplantation | pmid:11579294 |
| Roy A et al. | Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. | 2006 | Transplantation | pmid:16926593 |
| Welberry Smith MP et al. | Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. | 2013 | Transplantation | pmid:24056618 |
| Yang Z et al. | Long-term liver allograft survival induced by combined treatment with rAAV-hCTLA4Ig gene transfer and low-dose FK506. | 2003 | Transplantation | pmid:12589149 |
| Zhao WY et al. | Single kidneys transplanted from small pediatric donors less than 15 kilograms into pediatric recipients. | 2014 | Transplantation | pmid:25955345 |
| Benigni A et al. | The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. | 1992 | Transplantation | pmid:1279848 |
| Andoh TF et al. | Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. | 1994 | Transplantation | pmid:7509514 |
| Woodle ES et al. | A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. | 1996 | Transplantation | pmid:8830821 |
| Franz M et al. | Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? | 1998 | Transplantation | pmid:9825827 |
| Mathis AS et al. | Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. | 2001 | Transplantation | pmid:11374405 |
| Mañez R et al. | Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. | 1995 | Transplantation | pmid:7537400 |
| Singla AK et al. | Cerulomycin Caerulomycin [corrected] A: a potent novel immunosuppressive agent. | 2014 | Transplantation | pmid:24949498 |
| Chapman WC et al. | Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. | 2017 | Transplantation | pmid:28121741 |
| Walsh C et al. | Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients. | 2013 | Transplantation | pmid:23296149 |
| Becker T et al. | Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. | 2008 | Transplantation | pmid:19104406 |
| Muthukkumar S et al. | Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. | 1995 | Transplantation | pmid:7544036 |
| Oike F et al. | A 12-day course of FK506 allows long-term acceptance of semi-identical liver allograft in inbred miniature swine. | 2000 | Transplantation | pmid:10868630 |
| Gloor JM et al. | Subclinical rejection in tacrolimus-treated renal transplant recipients. | 2002 | Transplantation | pmid:12131699 |
| Borni-Duval C et al. | Risk factors for BK virus infection in the era of therapeutic drug monitoring. | 2013 | Transplantation | pmid:23778568 |
| Jain A et al. | Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. | 2005 | Transplantation | pmid:16210976 |
| Mourer JS et al. | Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients. | 2012 | Transplantation | pmid:22955227 |
| Florman S et al. | Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. | 2007 | Transplantation | pmid:17589349 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Yoo MC et al. | Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients. | 2015 | Transplantation | pmid:25539464 |
| Jain AB et al. | Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. | 1995 | Transplantation | pmid:7545836 |
| Vincenti F et al. | One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8669100 |
| Dean PG et al. | Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. | 2004 | Transplantation | pmid:15239621 |
| Tian L et al. | Association of the CD134/CD134L costimulatory pathway with acute rejection of small bowel allograft. | 2002 | Transplantation | pmid:12134113 |
| Gillard P et al. | Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. | 2008 | Transplantation | pmid:18212631 |